Selpercatinib’s expedited approval in 2020 has provided another treatment option for patients with metastatic RET fusion-positive NSCLC and metastatic RET mutant medullary thyroid cancers [84,85]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.